ANAB AnaptysBio, Inc.
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-3…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 AnaptysBio (ANAB) Is Down 7.6% After Tax-Driven Earnings Surge Masks Underlying Cash Performance AnaptysBio, Inc. previously reported fourth-quarter and six-month 2026 results showing net income of US$183.88 million for the quarter and US$131 million for the half-year, with basic earnings per share from continuing operations rising to US$6.06 for the quarter and US$6.09 for the six months. A key driver of the very large reported profit was a US$181.5 million income-tax benefit from releasing a deferred-tax valuation allowance following the separation of First Tracks Biotherapeutics, an... | ||
 AnaptysBio (ANAB) Reports a Tax-Driven Profit. When Will Royalties Fund Shareholder Returns? AnaptysBio, Inc. (NASDAQ:ANAB) reported $176.4 million of income from continuing operations for the six months ended June 30 in results released September 21. A $181.5 million income-tax benefit, primarily from releasing a deferred-tax valuation allowance, turned a $5.1 million pretax loss into that profit. The tax adjustment reflects greater expected use of tax assets following […] | ||
 AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates AnaptysBio (ANAB) delivered earnings and revenue surprises of +76.09% and +3.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB) Alphyn Capital Management, an investment management firm, released its second-quarter 2026 investor letter. The letter can be downloaded here. The fund’s Master Account returned 0.6% net in the quarter compared to 15.2% for the S&P500. As of June 30, 2026, the top ten positions comprised approximately 72% of the portfolio, and the portfolio held approximately […] | ||
GSK Eyes AnaptysBio (ANAB) Acquisition to Secure Drug Control Greenhaven Road Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund achieved an approximate 11% net return in the second quarter, indicating progress from the first quarter. Key changes to the portfolio will include lower concentration and increased investments with near-term catalysts, […] | ||
 CorMedix (CRMD) Q2 Earnings and Revenues Top Estimates CorMedix (CRMD) delivered earnings and revenue surprises of +11.54% and +7.64%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 What Makes AnaptysBio (ANAB) an Investment Bet? Laughing Water Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The second quarter was exceptionally good for the portfolio, with Class A investment in Laughing Water Capital returning approximately 39.8% net of all fees and expenses, bringing the YTD return to approximately 33.6% net. […] | ||